Non-invasive biomarkers have been utilized in many cancer types and include Human Epidermal Growth Factor Receptor 2 (HER2) (in breast tumors), BRAF V600E (in metastatic melanoma), Prostate Specific Antigen (PSA) (in prostate cancer) and Carcinoembryonic Antigen (CEA) (in colorectal cancer) [11,12]. This evidence concerns the gene CEACAM5 and prostate carcinoma.